2 active not recruiting, 1 completed, 1 recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Completed 1, Recruiting 1 |
Follow Neurofibroma, Plexiform: new trials by email Literature Review of Neurofibroma, Plexiform trials Research Report on Neurofibroma, Plexiform
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 177 | 2026-03-31 | 2026-05-27 |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 3 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 167 | 2023-06-20 | 2025-03-06 |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Selumetinib, Placebo - Neurofibromatosis 1, Plexiform Neurofibroma (PN) | Phase 3 | Active not recruiting | AstraZeneca | 145 | 2021-11-19 | 2026-11-12 |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Acceptance and Commitment Therapy (ACT) - Neurofibromatosis Type 1, Plexiform Neurofibromas | Phase 3 | Completed | National Cancer Institute (NCI) | 66 | 2015-07-07 | 2022-06-14 |
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Nerve Tissue (4) · Nerve Sheath Neoplasms (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Neurofibroma (4) · Neuromuscular Diseases (4) · Peripheral Nervous System Diseases (4) · Peripheral Nervous System Neoplasms (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Heredodegenerative Disorders, Nervous System (3) · Neoplastic Syndromes, Hereditary (3) · Neurocutaneous Syndromes (3)
AZD 6244 (1) · Acceptance and Commitment Therapy (1) · Control Groups (1)
AstraZeneca (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · National Cancer Institute (NCI) (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1)
China (3) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · Russia (1) · Spain (1) · United Kingdom (1)
Alice P. Chen, MD (1) · Staci M Peron, Ph.D. (1) · Wenbin Li, MD (1)